{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:16:47Z","timestamp":1790713007135,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ijrobp.2020.11.053","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T01:58:43Z","timestamp":1607047123000},"page":"1421-1430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study"],"prefix":"10.1016","volume":"109","author":[{"given":"Evert Jan","family":"Van Limbergen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hoeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Relinde I.Y.","family":"Lieverse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud","family":"Houben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Overhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Zindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"Verhelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig J.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther G.C.","family":"Troost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lambin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1076","key":"10.1016\/j.ijrobp.2020.11.053_bib1","doi-asserted-by":"crossref","first-page":"20170157","DOI":"10.1259\/bjr.20170157","article-title":"Combining radiotherapy with immunotherapy: the past, the present and the future","volume":"90","author":"Van Limbergen","year":"2017","journal-title":"Br J Radiol"},{"issue":"4","key":"10.1016\/j.ijrobp.2020.11.053_bib2","doi-asserted-by":"crossref","first-page":"e1414119","DOI":"10.1080\/2162402X.2017.1414119","article-title":"The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses","volume":"7","author":"Rekers","year":"2018","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.ijrobp.2020.11.053_bib3","doi-asserted-by":"crossref","first-page":"e1021541","DOI":"10.1080\/2162402X.2015.1021541","article-title":"Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2","volume":"4","author":"Rekers","year":"2015","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.ijrobp.2020.11.053_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.radonc.2015.06.019","article-title":"Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model","volume":"116","author":"Rekers","year":"2015","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.ijrobp.2020.11.053_bib5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1158\/1078-0432.CCR-14-2676","article-title":"Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects","volume":"21","author":"Zegers","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib6","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.V99.5.1659","article-title":"Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix","volume":"99","author":"Carnemolla","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib7","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/1878-0261.12705","article-title":"Human fibronectin Extra Domain B (ED-B) as a biomarker for targeted therapy in cancer","volume":"14","author":"Lieverse","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib8","first-page":"571","article-title":"Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer","volume":"9","author":"Santimaria","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V94.1.192.413k22_192_198","article-title":"A high-affinity human antibody that targets tumoral blood vessels","volume":"94","author":"Tarli","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib10","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.ejca.2010.07.033","article-title":"The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma","volume":"46","author":"Johannsen","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib11","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.1158\/1078-0432.CCR-11-1203","article-title":"A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma","volume":"17","author":"Eigentler","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib12","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1200\/JCO.2012.45.9651","article-title":"Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy","volume":"31","author":"Corbin","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijrobp.2020.11.053_bib13","first-page":"1547","volume":"7","author":"De Ruysscher","year":"2012"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/JTO.0b013e31824166a5","article-title":"Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer","volume":"7","author":"Hasselle","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib15","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.ijrobp.2012.02.054","article-title":"Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis","volume":"84","author":"Lopez Guerra","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cncr.23209","article-title":"A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions","volume":"112","author":"Milano","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib17","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.ijrobp.2008.03.044","article-title":"Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy","volume":"72","author":"Milano","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10549-008-0157-4","article-title":"Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy","volume":"115","author":"Milano","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib19","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","article-title":"Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective study","volume":"83","author":"Milano","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib20","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1002\/cncr.26611","article-title":"Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease","volume":"118","author":"Salama","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib22","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13014-020-01544-0","article-title":"Oligometastasis and local ablation in the era of systemic targeted and immunotherapy","volume":"15","author":"Mazzola","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib25","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib26","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic mon-small cell lung cancer: A phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.radonc.2018.02.022","article-title":"Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy","volume":"127","author":"Gabani","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jnci.2015.08.001","article-title":"Radiation induced liver disease: A clinical update","volume":"28","author":"Benson","year":"2016","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib29","first-page":"507","article-title":"Mechanisms of interleukin-2-induced hepatic toxicity","volume":"56","author":"Nakagawa","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12967-015-0397-0","article-title":"NHS-IL2 combined with radiotherapy: Preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy","volume":"13","author":"van den Heuvel","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.ijrobp.2020.11.053_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000773","article-title":"Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma","volume":"8","author":"Curti","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ijrobp.2020.11.053_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12885-020-07055-1","article-title":"Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial","volume":"20","author":"Lieverse","year":"2020","journal-title":"BMC Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620345934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620345934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:58:16Z","timestamp":1759744696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301620345934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0360301620345934"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.11.053","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.11.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}